Burcu Esen Akkaş

Is Eligibility Enough? Pretreatment Prediction of Failure to Reach a Second Cycle of [177Lu]Lu-PSMA Radioligand Therapy

Background/Objectives: Current guidelines define no absolute contraindication to prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), yet some patients receive only a single cycle. We aimed to characterize this single-cycle attrition (SCA) and derive an e...

Association of Complete Metabolic Response on Post-Neoadjuvant 18F-FDG PET/CT with Complete Cytoreduction in Advanced High-Grade Serous Tubo-Ovarian Carcinoma: A Retrospective Single-Center Cohort Study

Background/Objectives: To evaluate whether complete metabolic response (CMR) on 18F-FDG PET/CT after neoadjuvant chemotherapy (NACT) is associated with complete cytoreduction at interval debulking surgery (IDS), progression-free survival (PFS), and overall survival (OS) in patien...

Predictive value of the heterogeneity index in assessing treatment response using 18F-FDG PET/CT in locally advanced and advanced lung cancers.

OBJECTIVE: F-FDG) positron emission tomography/computed tomography (PET/CT)-based parameter to estimate this variability. This retrospective single-center study evaluated the predictive value of HI for treatment response in patients with locally advanced and advanced lung cancer...

Is 400 Gy enough for every tumor? The 3 cm cutoff and a modified BCLC classification for predicting complete response after radiation segmentectomy in hepatocellular carcinoma

To evaluate the relative contribution of the 400 Gy perfused liver absorbed dose (PLAD) threshold and tumor size in predicting complete response (CR) after yttrium-90 (Y-90) radiation segmentectomy (RS) in hepatocellular carcinoma (HCC), and to investigate the prognostic discrimi...